Gretchen Gignac, MD
Associate Professor
Boston University School of Medicine
Dept of Medicine
Hematology & Medical Oncology

MD, University of Pennsylvania School of Medicine



I am a medical oncologist who has clinical and research expertise in genitourinary medical oncology as well as clinical trials. My clinical practice is at Boston Medical Center and includes adult patients with cancers of the prostate, kidney, bladder, testicles and penis, as well as other solid cancers. My treatment expertise is in hormonal agents, chemotherapy, immunotherapy, targeted therapies, radioactive pharmaceuticals, bone targeted therapies, supportive and palliative care. I am also an educator in the Boston University School of Medicine and Boston Medical Center Hematology and Oncology Fellowship Program.

Active Staff Privileges
Boston Medical Center
Medicine




A PHASE 3, RANDOMIZED, DOUBLE-BLIND, MULTICENTER TRIAL COMPARING ORTERNEL (TAK-700) PLUS PREDNISONE
06/01/2011 - 11/16/2015 (PI)
Millennium Pharmaceuticals, Inc.

A RANDOMIZED PHASE 3 STUDY COMPARING CABAZITAXEL/PREDNISONE IN COMBINATION WITH CUSTIRSEN TO CABAZITAXEL/PREDNISONE FOR SECOND LINE CHEMOTHERAPY IN MEN WITH METASTATIC CASTRTE RESISTANT PROSTATE CANCE
09/28/2012 - 08/13/2015 (PI)
OncoGenex Technologies, Inc

A PHASE 3, RANDOMIZED, DOUBLE-BLIND, CONTROLLED STUDY OF CABOZANTINIB (XL184) VS. PREDNISONE IN METASTATIC CASTRATION RESISTANT PROSTATE CANCER PATIENTS WHO HAVE RECEIVED PRIOR COCETAXEL AND PRIOR ABI
10/19/2012 - 10/19/2014 (PI)
Exelixis, Inc

A Phase 3, Randomized, Double-Blind, Multicenter Trial Comparing Orteronel (TAK-700) Plus Prednisone with Placebo Plus Prednisone in Patients with Chemotherapy-Naive Metastatic Castration-Resistant Prostate Cancer
06/01/2011 - 05/31/2014 (PI)
Millennium Pharmaceuticals, Inc.

A PHASE 3, RANDOMIZED, DOUBLE-BLIND, MULTICENTER TRIAL COMPARING ORTERNEL (TAK-700) PLUS PREDNISONE
06/01/2011 - 05/31/2014 (PI)
Millennium Pharmaceuticals, Inc.




Yr Title Project-Sub Proj Pubs
Publications listed below are automatically derived from MEDLINE/PubMed and other sources, which might result in incorrect or missing publications. Faculty can login to make corrections and additions.

  1. Karantanos T, Karanika S, Seth B, Gignac G. The absolute lymphocyte count can predict the overall survival of patients with non-small cell lung cancer on nivolumab: a clinical study. Clin Transl Oncol. 2018 Jun 13.View Related Profiles. PMID: 29948974.
     
  2. Kan CK, Qureshi MM, Gupta A, Agarwal A, Gignac GA, Bloch BN, Thoreson N, Hirsch AE. Risk factors involved in treatment delays and differences in treatment type for patients with prostate cancer by risk category in an academic safety net hospital. Adv Radiat Oncol. 2018 Apr-Jun; 3(2):181-189.View Related Profiles. PMID: 29904743; DOI: 10.1016/j.adro.2017.12.002;.
     
  3. Karantanos T, Karanika S, Gignac G. Uncontrolled diabetes predicts poor response to novel antiandrogens. Endocr Relat Cancer. 2016 Sep; 23(9):691-8.View Related Profiles. PMID: 27515296; DOI: 10.1530/ERC-16-0222;.
     
  4. Gunnarsson O, Basaria S, Gignac GA. Cardiometabolic and skeletal risk factors in black men with prostate cancer starting androgen deprivation therapy. Cancers (Basel). 2015; 7(2):679-87. PMID: 25913100; DOI: 10.3390/cancers7020679;.
     
  5. Gunnarsson O, Basaria S, Gignac G. The prevalence of metabolic risk factors in black men with prostate cancer undergoing consideration for androgen-deprivation therapy. J Clin Oncol. 2011 May 20; 29(15_suppl):e15082. PMID: 28020432.
     
  6. Hirsch AE, Cuaron JJ, Janicek MJ, Mui K, Lee RJ, Wang DS, Babayan RK, Zumwalt AC, Gignac GA, Tao W, Ozonoff A, Zietman AL. Anatomic differences after robotic-assisted radical prostatectomy and open prostatectomy: implications for radiation field design. Pract Radiat Oncol. 2011 Apr-Jun; 1(2):115-25.View Related Profiles. PMID: 24673925; DOI: 10.1016/j.prro.2010.11.007;.
     
  7. Ariel E. Hirsch, John J. Cuaron, Milos J. Janicek, Kit Mui, Richard J. Lee, David S. Wang, Richard K. Babayan, Ann C. Zumwalt, Gretchen A. Gignac, Wen Tao, Alexander Ozonoff, Anthony L. Zietman et al. . Anatomic differences after robotic-assisted radical prostatectomy and open prostatectomy: implications for radiation field design. Practical Radiation Oncology. 2011; 1(2):115-125.
  8. Chi D, Hirsch AE, Gignac GA. Biochemical failure after radiation therapy for prostate cancer: Racial differences. J Clin Oncol. 2009 May 20; 27(15_suppl):e16071.View Related Profiles. PMID: 27963037.
     
  9. Dickstein RJ, Kreshover JE, Milose JC, Gignac GA. Metastatic prostate cancer at diagnosis: Clinical presentation in the post-PSA era. J Clin Oncol. 2009 May 20; 27(15_suppl):e16159. PMID: 27963401.
     
  10. Morris MJ, Pandit-Taskar N, Carrasquillo J, Divgi CR, Slovin S, Kelly WK, Rathkopf D, Gignac GA, Solit D, Schwartz L, Stephenson RD, Hong C, Delacruz A, Curley T, Heller G, Jia X, O'Donoghue J, Larson S, Scher HI. Phase I study of samarium-153 lexidronam with docetaxel in castration-resistant metastatic prostate cancer. J Clin Oncol. 2009 May 20; 27(15):2436-42. PMID: 19364960; PMCID: PMC2684850; DOI: 10.1200/JCO.2008.20.4164;.
     
Showing 10 of 15 results. Show More

This graph shows the total number of publications by year, by first, middle/unknown, or last author.

Bar chart showing 15 publications over 10 distinct years, with a maximum of 3 publications in 2009 and 2011

YearPublications
20021
20061
20072
20081
20093
20113
20151
20161
20171
20181

Available to Mentor as: (Review Mentor Role Definitions):
  • Advisor
  • Career Mentor
  • Project Mentor
Contact for Mentoring:
  • Email (see 'Contact Info')


820 Harrison Ave
Boston MA 02118
Google Map


Gignac's Networks
Click the "See All" links for more information and interactive visualizations
Concepts
_
Co-Authors
_
Similar People
_
Same Department